CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity.

British Journal of Haematology
F Lo CocoF Mandelli

Abstract

Seventeen patients with acute myeloid leukaemia (AML) whose blasts co-expressed the T-cell associated CD7 antibody were identified among 160 consecutive AML cases. Fourteen had FAB defined AML according to morphocytochemical criteria, whereas three patients were classified as 'MO' on the basis of immunophenotype. The incidence of CD7 positively was particularly significant in the less differentiated subtypes M0 and M1 compared with other FAB groups (P less than 0.001). In all cases the myeloid determinants CD13 and/or CD33 were associated with CD7 expression. Other B-lymphoid (CD10, CD19) or T-lymphoid (CD2, surface and cytoplasmic CD3) markers were analysed and found to be negative. Five out of 15 cases examined were TdT+. Clonal rearrangements of the immunoglobulin heavy chain (IgH) and/or T-cell receptor (TcR) beta chain genes were identified in only three out of 13 cases. Among these, one out of five co-expressing TdT showed IgH rearrangement when analysed at the DNA level. Clinical features at presentation and response to induction therapy did not allow us to consider CD7+ AML patients as a distinct subgroup with prognostic significance. Our data indicate that CD7 expression is a common finding in immature AML, being gener...Continue Reading

References

Feb 1, 1986·The Journal of Experimental Medicine·G Y ChengE A McCulloch
May 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·B F HaynesA S Fauci
Jul 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·D DiMaioT Maniatis
Jan 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·N MigoneL L Cavalli-Sforza

❮ Previous
Next ❯

Citations

Jan 1, 1994·Journal of Cancer Research and Clinical Oncology·N HaradaY Niho
Jan 1, 1992·Journal of Cancer Research and Clinical Oncology·S KondoT Shibuya
Aug 1, 1992·Cancer Genetics and Cytogenetics·L C ChanA Y Chan
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Jan 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·L E SchanbergR E Kaufman
May 1, 1991·British Journal of Haematology·T TeshimaY Niho
Feb 13, 2009·Acta Medica Croatica : C̆asopis Hravatske Akademije Medicinskih Znanosti·Drago BatinićBoris Labar
Nov 1, 1992·British Journal of Haematology·T EtoY Niho
Aug 1, 1991·Journal of Clinical Pathology·E GómezA López Borrasca
Jan 1, 1995·Genetica·R S Root-Bernstein, S H DeWitt
Mar 18, 2000·Leukemia & Lymphoma·Y TokunagaY Niho
Dec 1, 1993·Leukemia & Lymphoma·F Ferrara, L Del Vecchio
Jan 1, 1994·Leukemia & Lymphoma·M J Robertson, J Ritz
Jan 1, 1995·Leukemia & Lymphoma·A CuneoA Bardi
Jun 1, 1997·Leukemia & Lymphoma·P Lefterova, I G Schmidt-Wolf
Mar 1, 1995·Leukemia & Lymphoma·G Del PoetaG Papa
Jan 1, 1996·Cancer Investigation·A S Freedman
Mar 1, 1996·Baillière's Clinical Haematology·M A Sanz, A Sempere
Jul 31, 2007·Experimental and Molecular Pathology·Mohamed Abdelhaleem

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.